This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Amedisys (AMED) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Amedisys (AMED) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Amedisys (AMED) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of -12.28% and 0.08%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
The Pennant Group, Inc. (PNTG) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
The Pennant Group (PNTG) delivered earnings and revenue surprises of 13.04% and 3.49%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Waters Stock Gains on Earnings & Sales Beat in Q3, Raised View
by Zacks Equity Research
WAT's third-quarter 2024 results show growth in the pharma and industrial sectors. A dip in China sales creates headwinds.
AMED or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMED vs. CHE: Which Stock Is the Better Value Option?
Elanco Animal Health Incorporated (ELAN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Elanco Animal Health (ELAN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DVA Q3 Estimates Unchanged Before Earnings: How to Play the Stock?
by Debanjana Dey
Improvement in RPT is likely to have boosted DaVita's top line in the third quarter.
Zacks Industry Outlook Highlights Quest Diagnostics, Encompass Health, Amedisys and Addus HomeCare
by Zacks Equity Research
Quest Diagnostics, Encompass Health, Amedisys and Addus HomeCare have been highlighted in this Industry Outlook article.
4 Stocks to Buy in an Evolving Outpatient Home Health Industry
by Debanjana Dey
Dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, EHC, AMED and ADUS are well-poised to gain.
Will Amedisys (AMED) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Amedisys (AMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AMED vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMED vs. CHE: Which Stock Is the Better Value Option?
Amedisys (AMED) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Amedisys (AMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AMED or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMED vs. CHE: Which Stock Is the Better Value Option?
Waters (WAT) Q2 Earnings & Sales Beat Estimates, Fall Y/Y
by Zacks Equity Research
Waters' (WAT) second-quarter results are hurt by weak end-market momentum and softness in Asia, Americas and Europe.
Philips (PHG) Q2 Earnings Rise, Revenues Fall Year Over Year
by Zacks Equity Research
Philips' (PHG) second-quarter results benefit from strong momentum across the Diagnosis & Treatment, Connected Care and Personal Health businesses.
AMED vs. USPH: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMED vs. USPH: Which Stock Is the Better Value Option?
Amedisys (AMED) Q2 Earnings Top Estimates, Gross Margin Down
by Zacks Equity Research
Amedisys (AMED) delivers year-over-year growth in all three of its segmental revenues in the second quarter of 2024.
Compared to Estimates, Amedisys (AMED) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Amedisys (AMED) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Amedisys (AMED) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 8.20% and 2.05%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Quest Diagnostics Incorporated (DGX) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why Amedisys (AMED) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AMED or USPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMED vs. USPH: Which Stock Is the Better Value Option?
Encompass Health (EHC), Piedmont Expand Ties to Serve Georgia
by Zacks Equity Research
Encompass Health (EHC) expands its partnership with Piedmont to better serve Georgians with the Walton Rehabilitation Hospital.
AMED vs. USPH: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMED vs. USPH: Which Stock Is the Better Value Option?
Here's Why Amedisys (AMED) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.